Follow
David Machalz
David Machalz
Scientist Drug Discovery
Verified email at fu-berlin.de
Title
Cited by
Cited by
Year
Next generation 3D pharmacophore modeling
D Schaller, D Šribar, T Noonan, L Deng, TN Nguyen, S Pach, D Machalz, ...
Wiley Interdisciplinary Reviews: Computational Molecular Science 10 (4), e1468, 2020
1692020
Efficient substrate screening and inhibitor testing of human CYP4Z1 using permeabilized recombinant fission yeast
Q Yan, D Machalz, A Zoellner, EJ Sorensen, G Wolber, M Bureik
Biochemical pharmacology 146, 174-187, 2017
472017
Functional characterization and mechanistic modeling of the human cytochrome P450 enzyme CYP4A22
P Durairaj, L Fan, D Machalz, G Wolber, M Bureik
FEBS letters 593 (16), 2214-2225, 2019
252019
Structural insights into understudied human cytochrome P450 enzymes
D Machalz, S Pach, M Bermudez, M Bureik, G Wolber
Drug discovery today 26 (10), 2456-2464, 2021
222021
Importance of asparagine-381 and arginine-487 for substrate recognition in CYP4Z1
W Du, D Machalz, Q Yan, EJ Sorensen, G Wolber, M Bureik
Biochemical Pharmacology 174, 113850, 2020
192020
Functional expression of all human sulfotransferases in fission yeast, assay development, and structural models for isoforms SULT4A1 and SULT6B1
Y Sun, D Machalz, G Wolber, MK Parr, M Bureik
Biomolecules 10 (11), 1517, 2020
172020
Fine-mapping of the substrate specificity of human steroid 21-hydroxylase (CYP21A2)
A Stoll, S Loke, JF Joseph, D Machalz, X de la Torre, F Botre, G Wolber, ...
The Journal of Steroid Biochemistry and Molecular Biology 194, 105446, 2019
172019
Comparison of the three SARMs RAD-140, GLPG0492 and GSK-2881078 in two different in vitro bioassays, and in an in silico androgen receptor binding assay
O Zierau, A Kolodziejczyk, G Vollmer, D Machalz, G Wolber, D Thieme, ...
The Journal of steroid biochemistry and molecular biology 189, 81-86, 2019
152019
Discovery of a novel potent cytochrome P450 CYP4Z1 inhibitor
D Machalz, H Li, W Du, S Sharma, S Liu, M Bureik, G Wolber
European Journal of Medicinal Chemistry 215, 113255, 2021
142021
New proluciferin substrates for human CYP4 family enzymes
J Liu, D Machalz, G Wolber, EJ Sorensen, M Bureik
Applied Biochemistry and Biotechnology 193, 218-237, 2021
132021
A common polymorphic variant of UGT 1A5 displays increased activity due to optimized cofactor binding
F Yang, D Machalz, S Wang, Z Li, G Wolber, M Bureik
FEBS letters 592 (11), 1837-1846, 2018
132018
A benzoxazole derivative as an inhibitor of anaerobic choline metabolism by human gut microbiota
MT Gabr, D Machalz, S Pach, G Wolber
RSC Medicinal Chemistry 11 (12), 1402-1412, 2020
82020
Androgen-and estrogen-receptor mediated activities of 4-hydroxytestosterone, 4-hydroxyandrostenedione and their human metabolites in yeast based assays
AM Keiler, O Zierau, S Wolf, P Diel, W Schänzer, G Vollmer, D Machalz, ...
Toxicology Letters 292, 39-45, 2018
82018
Metabolism of the antipsychotic drug olanzapine by CYP3A43
J Zhao, D Machalz, S Liu, CA Wolf, G Wolber, MK Parr, M Bureik
Xenobiotica 52 (4), 413-425, 2022
42022
Corticosteroid biosynthesis revisited: No direct hydroxylation of pregnenolone by steroid 21-hydroxylase
S Loke, A Stoll, D Machalz, F Botrè, G Wolber, M Bureik, MK Parr
Frontiers in Endocrinology 12, 633785, 2021
22021
A convenient test system for the identification of CYP4V2 inhibitors
S Sharma, S Liu, P Durairaj, D Machalz, G Wolber, M Bureik
Molecular Vision 27, 601, 2021
12021
Deorphanizing Human Cytochrome P450 Enzymes CYP4A22 and CYP4Z1 through Mechanistic in silico modeling
D Machalz
2022
Corticosteroid Biosynthesis Revisited: Substrate Specificity of Steroid 21‐Hydroxylase
S Loke, A Stoll, JF Joseph, D Machalz, X de la Torre, F Botre, G Wolber, ...
The FASEB Journal 34 (S1), 1-1, 2020
2020
The system can't perform the operation now. Try again later.
Articles 1–18